ADMA ADMA Biologics Forecast, Technical & Fundamental Analysis
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
ADMA is expected to report earnings to rise 1.74% to 19 cents per share on November 11
Q3'26
Est.
$0.19
Q1'26
Missed
by $0.01
Q4'25
Beat
by $0.01
Q3'25
Est.
$0.15
Q2'25
Missed
by $0.01
The last earnings report on May 06 showed earnings per share of 18 cents, missing the estimate of 20 cents. With 1.48M shares outstanding, the current market capitalization sits at 2.14B.
A.I. Advisor
published General Information
General Information
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VCYT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VCYT could also see price increases.
ADMA saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for ADMA moved out of overbought territory on August 13, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 67 similar instances where the indicator exited the overbought zone. In of the 67 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ADMA moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ADMA broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on ADMA as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on August 04, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
ADMA moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 244 cases where ADMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ADMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.241) is normal, around the industry mean (20.109). P/E Ratio (13.643) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.468) is also within normal values, averaging (445.198).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
